The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•7 May 2026•

1 min read

Halozyme and GSK Partner to Develop Subcutaneous Oncology Treatments via ENHANZE

Key Facts

1Halozyme entered into a global collaboration and license agreement with GSK to use ENHANZE technology for subcutaneous oncology targets.

2The agreement includes developing subcutaneous formulations for multiple targets, including antibody drug conjugates (ADCs).

Halozyme Therapeutics has entered into a global collaboration and license agreement with GSK to advance oncology treatment delivery. Under the terms of the deal, GSK will leverage Halozyme's proprietary ENHANZE technology to develop subcutaneous formulations for multiple oncology targets. This partnership specifically focuses on antibody-drug conjugates (ADCs), aiming to convert traditional intravenous therapies into more convenient injections. The first clinical trial resulting from this strategic alliance is projected to initiate in 2026. This agreement underscores the value of Halozyme's drug delivery platform and provides significant long-term revenue potential through milestone payments and royalties. For GSK, the move strengthens its oncology pipeline and enhances patient accessibility to next-generation cancer treatments.